Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions.
For more information on Amplyx, please visit our website at www.amplyx.com
For more information on Amplyx, please visit our website at www.amplyx.com
Location: United States, California, San Diego
Employees: 11-50
Total raised: $207.7M
Investors 8
Funding Rounds 5
| Date | Series | Amount | Investors |
| 20.05.2020 | Series C | $90M | Sofinnova ... |
| 02.08.2017 | Series C | $67M | New Enterp... |
| 09.02.2016 | - | $8.7M | - |
| 11.11.2015 | Series B | $40.5M | - |
| 09.04.2010 | - | $1.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 03.12.2020 | Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting | |
| 06.11.2020 | Covid-19 roundup: Novartis treatment comes up short in PhIII; Humanigen expands trial, but draws criticism | A major player trying to adapt an anti-inflammatory for Covid-19 has seen the drug fall flat. Novartis reported Friday that a Phase III trial evaluating canakinumab in hospitalized Covid-19 cases with pneumonia and c... |
| 20.05.2020 | Amplyx closes $53 million Series C extension | - |
| 19.05.2020 | Amplyx Pharmaceuticals Closes $53M Series C Extension | Amplyx Pharmaceuticals, a San Diego, CA-based biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, closed a $53m Series C extension, which brings the Ser... |
| 19.05.2020 | Immune Therapeutics Company Amplyx Pharmaceuticals Adds $53M in a Series C Extension | - |
| 19.05.2020 | Amplyx Pharmaceuticals Adds $53M In Funding | San Diego-based Amplyx Pharmaceuticals has raised $53M in a Series C extension funding, bringing its Series C funding to over $90M, the comapny announced this morning. Amplyx--which is developing therapeutics for treating patients with comp... |
| 17.09.2019 | Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine | → Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning over some novel targets to see if the smaller player’s “systems biology” platform can yield better therapeutics. Starting with tw... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns. Paid Content What you need to know about growing cyberattacks From ExtraHop • This i... |
| 02.08.2017 | NEA Joins $67M Series C for Amplyx Pharmaceuticals | Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced that it has raised $67 million through a Series C financing led by Sofinnova Venture Partners and including other n... |
| 02.08.2017 | Amplyx Pharmaceuticals Raises $67m in Series C Financing | Amplyx Pharmaceuticals, a San Diego, CA-based company developing novel antifungal agents for life-threatening fungal infections, raised $67m in Series C financing. The round was led by Sofinnova Venture Partners with participation from othe... |
Show more